What is Going on with IPIX ?
Innovation Pharmaceuticals (IPIX) has announced that it has reached full patient enrollment for its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin. Brilacidin is currently being studied as a treatment to COVID-19 for moderate-to-severe cases in hospitalized patients, and is being studied under U.S. FDA Fast Track designation. Brilacidin has been suggested (based on pre-clinical studies) to be integral in disrupting viral integrity and is unaffected by mutations that result in COVID-19 variants. The total enrollment for this study is 120 patients across multiple sites. Early August is suspected to be the final data collection for the last patient enrolled in the study.
What This Means for IPIX?
This is good news for Innovation Pharmaceuticals as it positions itself strategically in the fight against the pandemic, while helping patients with more severe cases. Speaking on this, Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals, expresses that, “We are pleased to have reached this company milestone and particularly thank all of the participating investigator sites and patients, in addition to many others involved in supporting the completion of study enrollment, especially given the challenges brought on by the pandemic,” and, “Encouraged by extensive laboratory-based Brilacidin antiviral research focused on coronaviruses, and building on previous pre-clinical and clinical results demonstrating a robust Brilacidin therapeutic profile, we prioritized the development of Brilacidin as a novel antiviral. To us, this is much more than a COVID-19 study. Our goal is to develop a broad spectrum antiviral not just to help contain today’s pandemic, but also one that could be deployed against other infectious and deadly viruses that inevitably will follow. As such, we eagerly look forward to our Brilacidin COVID-19 trial readout.”
IPIX has an Overall Score of 20. Find out what this means to you and get the rest of the rankings on IPIX!
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.
